The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy

Tzong Shin Tzai, Nan-Haw Chow, Johnny Shinn Nan Lin, Wen-Horng Yang, Yat-Ching Tong

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: We evaluated whether p53 and bcl-2 expression has any predictive value on the outcome of postoperative adjuvant intravesical chemotherapy for superficial bladder transitional cell carcinoma (TCC). Materials and Methods: Immunostaining for p53 and bcl-2 was performed on paraffin-embedded tumor tissues obtained from 100 patients with superficial bladder TCC. 56 had solitary and 44 had multiple tumors; 36 were grade I, 53 grade II and 11 grade III; 50 were stage pTa and 50 stage pT1. They all received transurethral resection (TUR) and weekly intravesical instillation chemotherapy with either Thiotepa (70 patients) or Epirubicin (30 patients) for consecutive 8 doses postoperatively. Results: Overall, 7 (7%) tumors were p53+ and 12 (12%) tumors were bcl-2+. Of these, only one tumor was combined p53+ and bcl-2+. The status of tumor p53 and bcl-2 positivity was found to be not significantly correlated with either tumor grade or stage. After adjuvant intravesical chemotherapy, tumor recurrence is significantly correlated with tumor multifocality (p = 0.0002) but not with tumor grade and stage. Compared with p53- or bcl-2- tumors, patients with p53+ or bcl-2+ tumors do not show a higher tumor recurrence rate. The number of recurrence-free patients was also not significantly different in patients eventually developed disease progression, and none stained positively for either p53 or bcl-2. Conclusions: We conclude that in superficial bladder TCC the status of tumor p53 and bcl-2 expression is not correlated with stage of tumor p53 and bcl-2 expression is not correlated with stage and grade. Their expression, either alone or combined, has no predictive role on the outcome of post-TUR intravesical chemotherapy on tumor recurrence.

Original languageEnglish
Pages (from-to)4717-4721
Number of pages5
JournalAnticancer Research
Volume18
Issue number6 B
Publication statusPublished - 1998

Fingerprint

Transitional Cell Carcinoma
Urinary Bladder
Drug Therapy
Neoplasms
Recurrence
Adjuvant Chemotherapy
Thiotepa
Intravesical Administration
Epirubicin
Paraffin

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{c5e33f6ecbcf49b2af2cff97436cd8e1,
title = "The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy",
abstract = "Background: We evaluated whether p53 and bcl-2 expression has any predictive value on the outcome of postoperative adjuvant intravesical chemotherapy for superficial bladder transitional cell carcinoma (TCC). Materials and Methods: Immunostaining for p53 and bcl-2 was performed on paraffin-embedded tumor tissues obtained from 100 patients with superficial bladder TCC. 56 had solitary and 44 had multiple tumors; 36 were grade I, 53 grade II and 11 grade III; 50 were stage pTa and 50 stage pT1. They all received transurethral resection (TUR) and weekly intravesical instillation chemotherapy with either Thiotepa (70 patients) or Epirubicin (30 patients) for consecutive 8 doses postoperatively. Results: Overall, 7 (7{\%}) tumors were p53+ and 12 (12{\%}) tumors were bcl-2+. Of these, only one tumor was combined p53+ and bcl-2+. The status of tumor p53 and bcl-2 positivity was found to be not significantly correlated with either tumor grade or stage. After adjuvant intravesical chemotherapy, tumor recurrence is significantly correlated with tumor multifocality (p = 0.0002) but not with tumor grade and stage. Compared with p53- or bcl-2- tumors, patients with p53+ or bcl-2+ tumors do not show a higher tumor recurrence rate. The number of recurrence-free patients was also not significantly different in patients eventually developed disease progression, and none stained positively for either p53 or bcl-2. Conclusions: We conclude that in superficial bladder TCC the status of tumor p53 and bcl-2 expression is not correlated with stage of tumor p53 and bcl-2 expression is not correlated with stage and grade. Their expression, either alone or combined, has no predictive role on the outcome of post-TUR intravesical chemotherapy on tumor recurrence.",
author = "Tzai, {Tzong Shin} and Nan-Haw Chow and Lin, {Johnny Shinn Nan} and Wen-Horng Yang and Yat-Ching Tong",
year = "1998",
language = "English",
volume = "18",
pages = "4717--4721",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy

AU - Tzai, Tzong Shin

AU - Chow, Nan-Haw

AU - Lin, Johnny Shinn Nan

AU - Yang, Wen-Horng

AU - Tong, Yat-Ching

PY - 1998

Y1 - 1998

N2 - Background: We evaluated whether p53 and bcl-2 expression has any predictive value on the outcome of postoperative adjuvant intravesical chemotherapy for superficial bladder transitional cell carcinoma (TCC). Materials and Methods: Immunostaining for p53 and bcl-2 was performed on paraffin-embedded tumor tissues obtained from 100 patients with superficial bladder TCC. 56 had solitary and 44 had multiple tumors; 36 were grade I, 53 grade II and 11 grade III; 50 were stage pTa and 50 stage pT1. They all received transurethral resection (TUR) and weekly intravesical instillation chemotherapy with either Thiotepa (70 patients) or Epirubicin (30 patients) for consecutive 8 doses postoperatively. Results: Overall, 7 (7%) tumors were p53+ and 12 (12%) tumors were bcl-2+. Of these, only one tumor was combined p53+ and bcl-2+. The status of tumor p53 and bcl-2 positivity was found to be not significantly correlated with either tumor grade or stage. After adjuvant intravesical chemotherapy, tumor recurrence is significantly correlated with tumor multifocality (p = 0.0002) but not with tumor grade and stage. Compared with p53- or bcl-2- tumors, patients with p53+ or bcl-2+ tumors do not show a higher tumor recurrence rate. The number of recurrence-free patients was also not significantly different in patients eventually developed disease progression, and none stained positively for either p53 or bcl-2. Conclusions: We conclude that in superficial bladder TCC the status of tumor p53 and bcl-2 expression is not correlated with stage of tumor p53 and bcl-2 expression is not correlated with stage and grade. Their expression, either alone or combined, has no predictive role on the outcome of post-TUR intravesical chemotherapy on tumor recurrence.

AB - Background: We evaluated whether p53 and bcl-2 expression has any predictive value on the outcome of postoperative adjuvant intravesical chemotherapy for superficial bladder transitional cell carcinoma (TCC). Materials and Methods: Immunostaining for p53 and bcl-2 was performed on paraffin-embedded tumor tissues obtained from 100 patients with superficial bladder TCC. 56 had solitary and 44 had multiple tumors; 36 were grade I, 53 grade II and 11 grade III; 50 were stage pTa and 50 stage pT1. They all received transurethral resection (TUR) and weekly intravesical instillation chemotherapy with either Thiotepa (70 patients) or Epirubicin (30 patients) for consecutive 8 doses postoperatively. Results: Overall, 7 (7%) tumors were p53+ and 12 (12%) tumors were bcl-2+. Of these, only one tumor was combined p53+ and bcl-2+. The status of tumor p53 and bcl-2 positivity was found to be not significantly correlated with either tumor grade or stage. After adjuvant intravesical chemotherapy, tumor recurrence is significantly correlated with tumor multifocality (p = 0.0002) but not with tumor grade and stage. Compared with p53- or bcl-2- tumors, patients with p53+ or bcl-2+ tumors do not show a higher tumor recurrence rate. The number of recurrence-free patients was also not significantly different in patients eventually developed disease progression, and none stained positively for either p53 or bcl-2. Conclusions: We conclude that in superficial bladder TCC the status of tumor p53 and bcl-2 expression is not correlated with stage of tumor p53 and bcl-2 expression is not correlated with stage and grade. Their expression, either alone or combined, has no predictive role on the outcome of post-TUR intravesical chemotherapy on tumor recurrence.

UR - http://www.scopus.com/inward/record.url?scp=0032440016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032440016&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 4717

EP - 4721

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -